18 January 2023
Top 10 Events in Cell & Gene Therapy 2022
It’s day 1 of Advanced Therapies Week and Susan Nichols, Chief Business Officer at Virocell Biologics, has just finished presenting the top 10 events in the cell and gene therapy industry from 2022. In case you missed it, check out my summary, below.
Latest Content
Don’t Miss Out on Our Latest Webinar
Up Next: Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells
Are you looking to engineer your cells to manufacture healthy and highly functioning immune cells?
08:00 PDT | 11:00 EDT | 16:00 GMT
Zoom
Access Our Webinar Library
Our eBooks & Infographics
Gene-edited cell therapies represent a rapidly growing area for advanced therapeutic development, but manufacturing-related challenges remain to commercialize such complex therapies.
This Case Study demonstrates how the Excellos team successfully carried out process development of a scale up procedure from tissue culture stacks to a commercial bioreactor system.
This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment.
What are the steps on the long and winding road from the lab bench to the clinic for a novel gene therapy?
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
In this infographic, we have detailed some key considerations when choosing your plasmids for CAR-T development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.
Advanced therapies’ market access is a hot topic. Joining Phacilitate to shed some light on market access struggles are Director at NJ Redfern Limited and ex-bluebird bio UK GM Nicola Redfern, former SVP & CBO at Novartis Gene Therapies and current AviadoBio CEO Lisa Deschamps, and, Vice President and Global Head of Value and Access, at Novartis, Tay Salimullah.
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.
